Log In
BCIQ
Print this Print this
 

CD3 x HIV DART molecule (MGD014)

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody targeting CD3 and HIV-infected cells developed using MacroGenics' Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD3
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV/AIDS
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today